Traditionally, immune priming followed by an antigen-boost is utilized for vaccine-induced protective immunity and maintaining long-term immunity often requires repeated exposure to antigen. Here, a novel single dose vaccination platform designed with gonadotropin releasing hormone multiple antigenic peptide as a model antigen is shown. Initially a soluble component will prime the immune system followed by vaccine release from a biodegradable polyanhydride (PA) copolymer rod of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy) hexane (CPH) for immune boosting (Appendix A) [1] . A second PA-based vaccine depot is enclosed within an implant of biocompatible high molecular weight polyethylene, which limits PA degradation and antigen release to a single surface, significantly extending the release kinetics (Supplemental Table) . Collagen is used to generate an immunodiffusion barrier [2] over the PA wherein antigenantibody complex formation can occur for an immune feedback design (Fig. 1) . Therefore, antigen release is impeded, theoretically, by high antibody titers. The cap of the implant is a hydrophilic poly (vinylidene fluoride) membrane with 0.65-mm pores that allows flow of proteins into and out of the implant, while excluding leukocytes. Thus, this device enables vaccine priming, boost and long term maintenance with a single administration of antigen. 
